Core Viewpoint - OptimizeRx Corp. has appointed Steve Silvestro as the new Chief Executive Officer, effective March 10, 2025, to lead the company into its next phase of growth and transformation [1][3]. Company Leadership - Steve Silvestro has over 20 years of experience in health technology and services, having joined OptimizeRx in 2019 as Chief Commercial Officer and later serving as President and interim CEO [2][4]. - The Board of Directors conducted a thorough search for the new CEO, resulting in a unanimous decision to appoint Silvestro, who has been pivotal in enhancing the company's brand relevance and capabilities [3]. Strategic Focus - Silvestro aims to differentiate OptimizeRx through technology and strategic partnerships, emphasizing operational excellence and customer satisfaction [3]. - The company has completed a strategic review of its business processes and is focused on increasing recurring revenue and becoming a "Rule of 40" company, which refers to a combined growth and profit margin of 40% [3]. Company Overview - OptimizeRx is a leading healthcare technology company that connects life science brands with patients and healthcare providers through innovative AI-driven tools [5][6]. - The company is headquartered in Waltham, Massachusetts, and partners with major pharmaceutical and life sciences companies to improve healthcare outcomes [6].

Core Viewpoint - OptimizeRx Corp. is set to discuss its full year fiscal 2024 financial results and fourth quarter results on March 12, 2025, indicating a focus on transparency and engagement with investors [1]. Group 1: Conference Call Details - The conference call will take place on March 12, 2025, at 8:30 a.m. Eastern Time [2]. - Participants can join via a toll-free number or an international line, with specific access details provided [2]. - A replay of the call will be available for 12 months on the company's investor relations website [3]. Group 2: Company Overview - OptimizeRx provides innovative technology that enhances engagement between life sciences organizations, healthcare providers, and patients [4]. - The company has the capability to synchronize messaging across 2 million healthcare providers and over 240 million adults through various digital channels [4].

Company Leadership Transition - William J. Febbo, CEO of OptimizeRx, will depart the company effective December 31, 2024, to pursue other opportunities, while providing advisory services until March 31, 2025 [9] - Stephen Silvestro has been appointed as the interim CEO during the search for a new candidate, having previously served as Chief Commercial Officer and President [10] Company Growth and Strategy - OptimizeRx has experienced significant growth under Febbo's leadership, transforming from a single point of care product to an omnichannel platform, and is well-positioned for future growth [1] - The company reaffirms its financial guidance for the full year 2024, expecting to achieve results at the higher end of its revenue and adjusted EBITDA guidance range [2] Company Overview - OptimizeRx provides healthcare technology solutions that facilitate engagement between life sciences organizations, healthcare providers, and patients, connecting over 2 million U.S. healthcare providers through its digital point-of-care network [6]

Financial Performance - Net revenue for the three months ended September 30, 2024, was $21,309 thousand, a 30.5% increase from $16,331 thousand in the same period of 2023[6] - Gross profit for the nine months ended September 30, 2024, was $22,456 thousand, compared to $18,094 thousand for the same period in 2023, reflecting a 24.5% increase[6] - The company reported a net loss of $9,124 thousand for the three months ended September 30, 2024, compared to a net loss of $2,865 thousand in the same period in 2023[6] - The company reported a net loss of $20,032 thousand for the nine months ended September 30, 2024, compared to a net loss of $13,424 thousand for the same period in 2023, representing a 49.5% increase in losses[12] - The company reported a net loss of $9,124,000 for the three months ended September 30, 2024, compared to a net loss of $6,900,000 for the previous quarter[8] - The company had a net loss of $4,008,000 for the quarter ended June 30, 2024, indicating a worsening financial performance compared to the previous quarter[8] Operating Expenses - Total operating expenses for the three months ended September 30, 2024, were $22,009 thousand, up from $13,353 thousand in the same period of 2023, representing a 64.9% increase[6] - Stock-based compensation expense for options was $992,000 for the quarter ended September 30, 2024[8] - Stock-based compensation expenses for options and restricted stock amounted to $2,604,000 for the three months ended September 30, 2024[8] Cash and Assets - Cash and cash equivalents increased to $16,126 thousand as of September 30, 2024, from $13,852 thousand at the end of 2023, marking a 16.4% increase[5] - Total assets decreased to $165,199 thousand as of September 30, 2024, down from $183,374 thousand at the end of 2023, a decline of 9.9%[5] - Accounts receivable decreased to $26,327,000 as of September 30, 2024, down from $36,253,000 at the end of 2023, indicating a decline of 27.5%[5] - Cash provided by operating activities was $4,691 thousand for the nine months ended September 30, 2024, compared to cash used in operating activities of $982 thousand in the same period of 2023[12] - Cash and cash equivalents at the end of the period were $16,126 thousand, an increase from $9,923 thousand at the end of the same period in 2023[12] Equity and Shares - As of September 30, 2024, the total stockholders' equity for OptimizerX Corporation is $114,465,000, down from $126,553,000 at the beginning of the year, reflecting a net loss of $84,290,000[8] - The total number of common shares outstanding increased to 20,069,432 as of September 30, 2024, from 19,899,679 at the beginning of the year[8] - The weighted average number of shares outstanding for basic loss per share was 18,323,542 for the three months ended September 30, 2024, compared to 16,637,606 for the same period in 2023[6] - The accumulated deficit increased to $84,290,000 as of September 30, 2024, compared to $64,258,000 at the beginning of the year[8] Goodwill and Impairment - The company recorded a goodwill impairment of $7,489 thousand for the three months ended September 30, 2024[6] - Goodwill impairment of $7,489 thousand was recorded during the nine months ended September 30, 2024, indicating a significant decline in the company's market capitalization[12] - The company experienced a triggering event for goodwill impairment testing due to a sustained decline in stock price and market capitalization[33] - As of September 30, 2024, the carrying amount of goodwill was $70.9 million, down from $78.4 million as of December 31, 2023, with a noncash goodwill impairment charge of $7.5 million recorded[34] Debt and Liabilities - The company entered into a $40 million term loan on October 11, 2023, related to the acquisition of Medicx Health, with long-term debt net amounting to $33.3 million as of September 30, 2024[35] - The term loan bears an interest rate of 14.0%, with an effective rate of 16.1% after accounting for debt issuance costs[35] - The company is required to make mandatory prepayments on the term loan based on Excess Cash Flow, with percentages ranging from 25% to 75% depending on the leverage ratio[38] - Total lease liabilities as of September 30, 2024, amounted to $437,000, with future minimum lease payments totaling $482,000[43] Revenue Recognition - Revenue recognition policies include unbilled amounts of $6.0 million as of September 30, 2024, compared to $3.3 million at December 31, 2023[59] - The net contract balance for contracts in progress increased significantly to $23.2 million as of September 30, 2024, from $2.0 million at December 31, 2023[61] - Deferred revenue as of September 30, 2024, was $786,000, compared to $188,000 as of September 30, 2023, indicating a significant increase[65] - Revenue recognized over time for the nine months ended September 30, 2024, was $54,189,000, compared to $40,421,000 for the same period in 2023, reflecting a year-over-year increase of 34.0%[69] Tax and Commitments - The effective tax rate for the three months ended September 30, 2024, was 8.2%, with a tax benefit of $817,000 reported[80] - Commitments for future minimum payments as of September 30, 2024, totaled $16.7 million, with payments due from 2024 to 2028[79] Acquisitions - The company acquired 100% of Healthy Offers, Inc. (Medicx Health) on October 24, 2023, which is expected to enhance its digital health technology offerings[18] - Pro forma revenue for the three months ended September 30, 2023, including Medicx Health, was $23,852 thousand, while the net loss for the same period was $3,484 thousand[19]

Group 1: Earnings Performance - OptimizeRx Corp. reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and up from $0.09 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $21.31 million for the quarter ended September 2024, which missed the Zacks Consensus Estimate by 14.55%, compared to year-ago revenues of $16.33 million [2] - Over the last four quarters, OptimizeRx has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Group 2: Stock Performance and Outlook - OptimizeRx shares have declined approximately 59.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is $0.39 on revenues of $37.55 million, and for the current fiscal year, it is $0.36 on revenues of $93.34 million [7] Group 3: Industry Context - The Computer - Software industry, to which OptimizeRx belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact OptimizeRx's stock performance [5]

Exhibit 99.1 OptimizeRx Reports Third Quarter 2024 Financial Results - Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 WALTHAM, Mass. – November 13, 2024 – OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the th ...

Company Overview - OptimizeRx Corp. (OPRX) shares increased by 19.8% to close at $6.12, following a notable trading volume, contrasting with a 27.4% loss over the past four weeks [1] - The company is experiencing strong growth through its Dynamic Audience Activation Platform, which provides predictive and secure marketing across a network connecting patients, healthcare providers, and the life sciences sector [1] Earnings Expectations - The upcoming quarterly earnings report is expected to show earnings of $0.06 per share, reflecting a year-over-year decrease of 33.3%, while revenues are projected to be $24.94 million, an increase of 52.7% from the previous year [2] - The consensus EPS estimate for OptimizeRx has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - OptimizeRx is categorized within the Zacks Computer - Software industry, where Intuit (INTU) also operates, having closed 4.8% higher at $648.39, with a 0.9% return over the past month [3] - Intuit's consensus EPS estimate has seen a slight increase of 0.1% to $2.36, representing a year-over-year change of -4.5%, and currently holds a Zacks Rank of 4 (Sell) [4]

WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management wil ...

OptimizeRx Corp. (OPRX) shares soared 5.4% in the last trading session to close at $7.59. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks. The increase in share price can be attributed to higher demand for the company's innovative DAAP (Dynamic Audience Activation Platform) solution. The platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences acr ...

WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over $10 million, which includes the previously mentioned $6 million DAAP contract. This initia ...